Equities analysts expect that Biohaven Pharmaceutical Holding Co Ltd (NYSE:BHVN) will report earnings of ($1.97) per share for the current quarter, according to Zacks. Zero analysts have issued estimates for Biohaven Pharmaceutical’s earnings. The lowest EPS estimate is ($2.36) and the highest is ($1.60). Biohaven Pharmaceutical posted earnings per share of ($1.34) during the same quarter last year, which would indicate a negative year over year growth rate of 47%. The firm is scheduled to announce its next quarterly earnings report on Thursday, February 27th.
On average, analysts expect that Biohaven Pharmaceutical will report full-year earnings of ($9.88) per share for the current financial year, with EPS estimates ranging from ($10.40) to ($8.83). For the next financial year, analysts expect that the company will report earnings of ($6.78) per share, with EPS estimates ranging from ($8.71) to ($5.12). Zacks Investment Research’s EPS averages are a mean average based on a survey of analysts that that provide coverage for Biohaven Pharmaceutical.
Biohaven Pharmaceutical (NYSE:BHVN) last issued its quarterly earnings results on Friday, November 1st. The company reported ($2.04) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($1.57) by ($0.47).
BHVN has been the topic of a number of recent research reports. Goldman Sachs Group set a $89.00 price target on shares of Biohaven Pharmaceutical and gave the stock a “buy” rating in a research note on Wednesday, September 4th. Canaccord Genuity set a $80.00 price target on shares of Biohaven Pharmaceutical and gave the stock a “buy” rating in a research note on Monday, August 26th. Morgan Stanley set a $50.00 price target on shares of Biohaven Pharmaceutical and gave the stock a “hold” rating in a research note on Friday, August 9th. Oppenheimer set a $67.00 price target on shares of Biohaven Pharmaceutical and gave the stock a “buy” rating in a research note on Wednesday, October 9th. Finally, ValuEngine lowered shares of Biohaven Pharmaceutical from a “hold” rating to a “sell” rating in a research note on Thursday. One investment analyst has rated the stock with a sell rating, three have issued a hold rating and eight have given a buy rating to the company. The stock presently has an average rating of “Buy” and an average price target of $71.80.
NYSE:BHVN traded up $2.06 on Friday, reaching $51.08. 881,221 shares of the company’s stock were exchanged, compared to its average volume of 487,177. The firm has a market capitalization of $2.56 billion, a price-to-earnings ratio of -8.31 and a beta of 0.34. The business has a fifty day moving average of $45.01 and a 200-day moving average of $47.68. Biohaven Pharmaceutical has a 52-week low of $29.17 and a 52-week high of $67.86.
In related news, insider Elyse Stock sold 17,700 shares of the company’s stock in a transaction that occurred on Friday, October 18th. The stock was sold at an average price of $45.07, for a total value of $797,739.00. Following the completion of the transaction, the insider now directly owns 17,700 shares of the company’s stock, valued at $797,739. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Eric Aguiar sold 10,000 shares of the company’s stock in a transaction that occurred on Wednesday, September 11th. The shares were sold at an average price of $45.00, for a total value of $450,000.00. The disclosure for this sale can be found here. Over the last three months, insiders have sold 28,500 shares of company stock valued at $1,283,747. Corporate insiders own 23.90% of the company’s stock.
A number of institutional investors and hedge funds have recently made changes to their positions in BHVN. Nuveen Asset Management LLC acquired a new position in Biohaven Pharmaceutical in the second quarter valued at approximately $38,799,000. Bank of New York Mellon Corp boosted its holdings in Biohaven Pharmaceutical by 236.8% in the second quarter. Bank of New York Mellon Corp now owns 545,594 shares of the company’s stock valued at $23,892,000 after purchasing an additional 383,594 shares in the last quarter. Brown Advisory Inc. boosted its holdings in Biohaven Pharmaceutical by 60.7% in the second quarter. Brown Advisory Inc. now owns 1,008,046 shares of the company’s stock valued at $44,144,000 after purchasing an additional 380,764 shares in the last quarter. Vanguard Group Inc. boosted its holdings in Biohaven Pharmaceutical by 34.2% in the second quarter. Vanguard Group Inc. now owns 1,154,257 shares of the company’s stock valued at $50,545,000 after purchasing an additional 294,098 shares in the last quarter. Finally, Luminus Management LLC acquired a new position in Biohaven Pharmaceutical in the second quarter valued at approximately $12,572,000. 88.91% of the stock is owned by hedge funds and other institutional investors.
Biohaven Pharmaceutical Company Profile
Biohaven Pharmaceutical Holding Company Ltd., a clinical-stage biopharmaceutical company, develops late-stage products candidates targeting neurological diseases in the United States. Its clinical stage products include Rimegepant, a product that has completed phase III trials and is in long-term safety ongoing process for acute treatment and prevention of migraine; BHV-3500 that has completed phase I clinical trial for acute treatment and prevention of migraine; and Troriluzole that has completed II/III randomization phase and is ongoing extension trial for ataxias.
Read More: Book Value Per Share in Stock Trading
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Biohaven Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biohaven Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.